Table 2.
Associations of HPV16, high-risk (HR) oncogenic HPV and other alpha HPV types with risks of esophageal cancer and histological type
| All Esophageal Cancers | ||||||
|---|---|---|---|---|---|---|
| Alpha HPV Type | Cases (n=125) | Controls (n=371)† | Adjusted Model* | Permutated Pξ |
||
| N (%) | N (%) | OR† | 95% CI | p | ||
| HPV16 | 1 (0.8) | 6 (1.6) | 0.54 | 0.10 – 4.84 | 0.58 | >0.999 |
| HR-HPVs‡ excluding HPV16 | 8 (6.4) | 18 (4.9) | 1.21 | 0.49 – 2.99 | 0.68 | >0.999 |
| Non-HR HPV types | 16 (12.8) | 36 (9.7) | 1.47 | 0.77 – 2.81 | 0.24 | 0.801 |
| Any Alpha HPV | 23 (18.4) | 53 (14.3) | 1.39 | 0.78 – 2.48 | 0.26 | 0.823 |
| Esophageal Squamous Cell Carcinoma (ESCC) | ||||||
| Alpha HPV Type | Cases (n=28) | Controls (n=83) | OR† | 95% CI | p | Permutated Pξ |
| HPV16 | 0 (0) | 1 (1.2) | - | - | - | >0.999 |
| HR-HPVs‡ excluding HPV16 | 3 (10.7) | 1 (1.2) | 10.52 | 1.01 – 108.5 | 0.048 | 0.236 |
| Non-HR HPV types | 4 (14.3) | 11 (13.3) | 1.68 | 0.41 – 6.91 | 0.48 | >0.999 |
| Any Alpha HPV | 6 (21.4) | 13 (15.7) | 2.21 | 0.61 – 8.05 | 0.23 | 0.772 |
| Esophageal Cancer: Adeno-Carcinoma | ||||||
| Alpha HPV Type | Cases (n=80) | Controls (n=238) | OR† | 95% CI | p | Permutated Pξ |
| HPV16 | 1 (1.3) | 5 (2.1) | 0.60 | 0.10 – 5.85 | 0.66 | >0.999 |
| HR-HPVs‡ excluding HPV16 | 3 (3.8) | 14 (5.9) | 0.52 | 0.14 – 1.96 | 0.33 | >0.999 |
| Non-HR HPV types | 8 (10.0) | 21 (8.8) | 1.21 | 0.51 – 2.86 | 0.66 | >0.999 |
| Any Alpha HPV | 12 (15.0) | 35 (14.6) | 0.98 | 0.46 – 2.08 | 0.96 | >0.999 |
†
One control had missing alpha HPV exposure and thus was excluded from these analyses
*
OR and 95% CI were estimated from conditional logistic regression models adjusted for smoking, alcohol consumption and study cohort.
‡
High-risk oncogenic (HR) HPVs include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59
ξ
Permutated P-values were calculated to account for multiple comparisons (see methods)